CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: July-15-11
Credit Expiration Date: July-15-12


Gary Owens, MD
Gary Owens Associates
Medical Management and Pharmaceutical Consulting
Glen Mills, PA

Credit Hours

Physicians CME: 1 credit
Nursing CE: 1 contact hour
Pharmacist CPE: 1 contact hour (0.1 CEU)


Online Presentation

Program Description

Each year approximately 3 million U.S. adults are affected by gout, and the incidence and prevalence are rising. This rise in gout and hyperuricemia has been attributed to the increasing at-risk population, including patients with hypertension, diabetes, hyperlipidemia, chronic kidney disease, and the metabolic syndrome. Notwithstanding, gout is still one of the most treatable forms of arthritis; and, with proper treatment, patients are likely to avoid serious consequences. However, advanced age, comorbidities, and drug-drug interactions can complicate treatment and often lead to medical errors in the treatment of gout.

The progression of gout can be slowed with earlier, more accurate diagnosis. However, gout is frequently misdiagnosed or diagnosed late in the course of the illness. In addition, suboptimal management of gout is recognized as a likely contributor to the recent rise in symptomatic, chronic gout. Clinical management of gout continues to lag behind recent advances and the current evidence-based best practices, underscoring the need for continuing education on gout management.

Program Developer/Facilitator


Target Audience

This educational activity has been designed for managed care directors, physicians, pharmacists, nurses, case managers, and other health care professionals interested in managed care issues related to gout management.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Describe the health and economic consequences that can occur when chronic gout is not managed appropriately.
  2. Discuss risk factors for gout in specific patient populations, including factors contributing to the increasing prevalence of gout in women and patients with metabolic syndrome.
  3. Compare the risks and benefits of pharmacologic agents currently available to treat acute gout and underlying hyperuricemia.
  4. Compare the cost-efficacy of chronic outpatient gout therapy vs hospitalization.
  5. Recognize the benefits of long-term management of hyperuricemia.


It is the policy of the accredited providers to ensure balance, independence, objectivity and scientific rigor in all continuing education programs. Faculty must disclose to program participants the existence of any significant financial interest or any other relationship with the manufacturer of any commercial product(s) discussed in an educational presentation.

Dr. Owens discloses that he has served as a Consultant to Auxilium Pharmaceuticals, OncoMed, Allergan, Eyetech, and Johnson & Johnson; has served on Advisory Boards for Pfizer, Eli Lilly, and Amgen; and has conducted Market Research for Centocor Ortho Biotech and Pfizer.

Planning committee:
Katie Eads of NAMCP has no financial relationships that present a real or perceived conflict of interest.
Sara Thier of Medical Communication Media has no financial relationships that present a real or perceived conflict of interest.
Beth Paczolt, MD of Medical Communication Media currently has no financial relationships that present a real or perceived conflict of interest. Prior to joining Medical Communications Media she served as a Medical Director of a promotional medical communications company where her organization received funding from Gilead Sciences, Novartis, Merck, and Ortho-Mcneil Janssen.

Please note: The opinions expressed in this program should not be construed as those of the CME/CNE provider. The information and views are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this program may include the use of drugs for unlabeled indications. Use of drugs outside of labeling should be considered experimental, and participants are advised to consult prescribing information and professional literature.

Credit Statements

Physicians: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the National Association of Managed Care Physicians (NAMCP) and Medical Communications Media, Inc. The NAMCP is accredited by the ACCME to provide continuing medical education to physicians.

NAMCP designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: The American Association of Managed Care Nurses has been approved as a provider of continuing education by the Virginia Nurses Association (VNA). VNA is accredited as an approver of Continuing Education in nursing by the American Nurses Credentialing Center's Commission on Accreditation. 1.0 contact hour will be awarded to nurses who complete this activity.

Pharmacists: ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 221-999-11-029-H01-P has been assigned to this home-study knowledge-based program (initial release date 07-15-11). This program is approved for 1.0 contact hour (0.10 CEU) in states that recognize ACPE providers. The program is provided at no cost to participants.

Statements of credit will be issued online at upon successful completion of the program evaluation. Participants must attend the entire program, complete a program evaluation, and complete a post-test with a score of 70% or higher to receive pharmacy CE credit. No partial credit will be given.

Commercial Support Statements

Supported through an educational grant from Takeda Pharmaceuticals North America, Inc.


Minimum Hardware/Software Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7. Or, Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers • High-speed internet connection • Internet Explorer 6.x or higher, Firefox 2.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser • Adobe Flash Player and/or an HTML5 capable browser may be required for video or audio playback • Adobe Acrobat Reader

  1. Please turn off all pop-up blockers to assure access to the educational activity.
  2. Click on the "Start program" icon at the bottom of this page. If you are not already registered as a user of this website, this will bring you to the login/registration page where you will be able to register as a new member or check existing registration information. When ready, click on the "Continue to Program" icon at the bottom of the screen.
  3. The activity will take approximately 630 minutes to complete.
  4. After the activity has finished, click on the "Post-test" button.
  5. Instructions for completing and submitting the post-test and evaluation are provided on the post-test screen.

Certificate Fee



©2011, NAMCP and Medical Communications Media, Inc. All rights reserved. This activity is designed to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. None of the contents may be reproduced in any form without prior written permission from NAMCP and the publisher. The opinions expressed in this presentation are those of the speaker and do not necessarily reflect the opinions or recommendations of the affiliated institutions, the publisher, NAMCP, or Takeda Pharmaceuticals North America. Any medications or other diagnostic or treatment procedures discussed by the program speakers should not be utilized by clinicians without evaluation of their patients’ conditions and possible contraindications or risks or without a review of any applicable manufacturer’s product information and comparison with the recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu